Chemotherapy maintenance

Pashtoon Murtaza Kasi, Axel F Grothey

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Over the years, there has been a treatment paradigm shift for patients with metastatic colorectal cancer with the emergence of the concept of "Continuumof Care" as optimal palliative therapy strategy. This concept is reflected in the induction-maintenance approach in first-line therapy, which is meant to prolong the duration of tumor-directed therapy while mitigating treatment-related toxicities. Traditionally, maintenance chemotherapy refers to the utilization of regimens with less toxicity after the initial upfront treatment. The need for this rose over the years because of significantly improved survival of patients with metastatic colorectal cancer. The classic study using the principles of maintenance chemotherapy options is illustrated well in the recently published CAIRO-3 study by the Dutch Colorectal Cancer Group. There is still an unmet need. Using novel agents alone or in various combinations with biologics through trials utilizing clinically relevant endpoints and efficient clinical trial designs are important considerations.

Original languageEnglish (US)
Pages (from-to)199-204
Number of pages6
JournalCancer Journal (United States)
Volume22
Issue number3
DOIs
StatePublished - 2016

Keywords

  • Bevacizumab
  • Biologics
  • Cetuximab
  • Chemotherapy
  • EGFR
  • Erlotinib
  • Maintenance
  • Metastatic colorectal cancer (mCRC)
  • Panitumumab
  • RAS
  • Regorafenib
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy maintenance'. Together they form a unique fingerprint.

  • Cite this